Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R1

FGF R1

Brief Information

Name:Fibroblast growth factor receptor 1
Target Synonym:EC:2.7.10.1,FGFR1/PLAG1 Fusion,HH2,EC 2.7.10,FLG,FLT2,CEK,BFGFR,FGFBR,bFGF-R-1,Proto-oncogene c-Fgr,Fibroblast growth factor receptor 1,CD331,FGFR1,Basic Fibroblast Growth Factor Receptor 1,Fms-Related Tyrosine Kinase 2,FGFR-1,FLT-2,HBGFR,Heparin-Binding Growth Factor Receptor,FMS-Like Tyrosine Kinase 2,Hydroxyaryl-Protein Kinase,Pfeiffer Syndrome,CD331 Antigen,EC 2.7.10.1,HRTFDS,N-Sam,ECCL,KAL2,OGD,Receptor, Fibroblast Growth Factor, Type 1
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FG1-H5289 Human Human FGF R1 / CD331 Protein, Strep Tag
FG1-H5289-structure
FG1-H5289-sds
FG1-H5223 Human Human FGF R1 / CD331 Protein, His Tag (SPR verified)
FG1-H5223-structure
FG1-H5223-sds
FG1-H5223-elisa_1
FG1-H5223-elisa_2

Part of Bioactivity data

FG1-H5223-BLI
Human_FcRn_Heterodimer_Protein_SPR

Human FGF R1, His Tag (Cat. No. FG1-H5223) captured on CM5 chip via anti-His antibody can bind Human FGF acidic, Tag Free (Cat. No. FAFF-H4116) with an affinity constant of 55.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

FGFR1,BFGFR,CD331,CEK,FGFBR,FLG,HBGFR,N-SAM,FLT2,H2,KAL2,FLJ14326

Background

Fibroblast growth factor receptor 1 (FGFR1) is also known as basic fibroblast growth factor receptor 1(BFGFR1), FMS-like tyrosine kinase, CD331, and is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. This protein is one of several fibroblast growth factor receptors, which are related proteins that are involved in important processes such as cell division, regulation of cell growth and maturation, formation of blood vessels, wound healing, and embryonic development.The FGFR1 protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with specific growth factors outside the cell and to receive signals that help the cell respond to its environment. When growth factors attach to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. The FGFR1 protein is thought to play an important role in the development of the nervous system. This protein may also help regulate the growth of long bones, such as the large bones in the arms and legs.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Lymphoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Surufatinib HMPL-012 Approved Hutchison Medipharma Ltd 苏泰达, SULANDA Mainland China Neuroendocrine Tumors Hutchison Huangpu Medicine (Shanghai) Co Ltd 2020-12-29 Solid tumours; Hematologic Neoplasms; Biliary Tract Neoplasms; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Bile Duct Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine Details
Pazopanib Hydrochloride GW-786034; SB-786034; GSK-786034; GW-786034B Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Patorma, Votrient Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic Details
Pemigatinib INCB-054828; IBI-375; INCB-54828; BH-009 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 Hong Kong Biliary Tract Neoplasms Innovent Biologics(Suzhou) Co Ltd 2020-04-17 Biliary Tract Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Translocation, Genetic; Bile Duct Neoplasms; Endometrial Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer Ag Resihance, Stivarga Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Endometrial Neoplasms Eisai Co Ltd 2015-02-13 Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Endometrial Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Sarcoma, Alveolar Soft Part; Gallbladder Neoplasms; Medullary thyroid cancer (MTC); Thyroid Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Osteoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Genital Diseases, Female; Leiomyosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Sarcoma; Bile Duct Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
TT-00434 TT-00434 Phase 1 Clinical Yaojie Ankang (Nanjing) Technology Co Ltd Solid tumours; Urinary Bladder Neoplasms Details
S-49076 S-49076 Phase 2 Clinical Servier Glioblastoma; Carcinoma, Non-Small-Cell Lung Details
CH-5183284 FF-284; CH-5183284; Debio-1347 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Breast Neoplasms Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
Sprifermin zFGF-5; Zfgf5; AS-902330; rhFGF-18; trFGF-18; FGF-18 Phase 2 Clinical Zymogenetics Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee; Osteoarthritis Details
PRN-1371 PRN-1371 Phase 1 Clinical Principia Biopharma Inc Solid tumours; Urinary Bladder Neoplasms Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
AZD-4547 AZD-4547; ABSK-091; AZD4547; ABSK091 Phase 2 Clinical Astrazeneca Plc Solid tumours; Gastrointestinal Diseases; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms Details
RG-7992 RG-7992; BFKB-8488A; RO-7040551 Phase 2 Clinical Genentech Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 2 Clinical Bristol-Myers Squibb Company Liver Neoplasms; Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Sarcoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
NGM-313 MK-3655; NGM-313 Phase 2 Clinical Ngm Biopharmaceuticals Non-alcoholic Fatty Liver Disease; Hepatitis; Obesity Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Huangpu Medicine (Shanghai) Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms, Mesothelial; Mesothelioma; Bile Duct Neoplasms Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 1 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
E-7090 E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
Futibatinib TAS-120 Phase 3 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Bone Marrow Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message